Madrigal Pharmaceuticals Inc. (MDGL)

97.53
6.01 5.80
NASDAQ : Health Technology
Prev Close 103.54
Open 103.23
Day Low/High 96.50 / 103.23
52 Wk Low/High 89.83 / 315.00
Volume 202.63K
Avg Volume 190.30K
Exchange NASDAQ
Shares Outstanding 15.42M
Market Cap 1.60B
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Here's a Handful of Small Biotechs Where Insiders Are Buying

Here's a Handful of Small Biotechs Where Insiders Are Buying

Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.

MDGL: Insiders Vs. Shorts

MDGL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Madrigal Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 5.57 "days to cover" versus the median component at 4.44. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

My Stock of the Week: ENDRA Life Sciences

My Stock of the Week: ENDRA Life Sciences

I'm simply focusing on individual stocks at this point and am not too concerned about the macro picture.

Watch the Small-Cap Stocks, They Are the Key to This Market

Watch the Small-Cap Stocks, They Are the Key to This Market

The good news is there doesn't seem to be much concern about trade wars and steel tariffs.

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

Markets Face Heavy News Flow in Next 48 Hours

Markets Face Heavy News Flow in Next 48 Hours

In addition to the State of the Union address and the Fed interest rate decision, companies representing about 25% of the Nasdaq 100's market cap will report results in the next two days.

Madrigal Pharmaceuticals Reaches Analyst Target Price

Madrigal Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Madrigal Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $113.33, changing hands for $124.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

The Stock Market Is Facing One Big Obstacle Right Now

The Stock Market Is Facing One Big Obstacle Right Now

You have to wonder how much longer we can run without a pullback of at least 2%.

You Can't Reason With a Steamroller

You Can't Reason With a Steamroller

The momentum is crushing everything in its way.

Cara Therapeutics, Thomson Reuters, Wynn Resorts: 'Mad Money' Lightning Round

Cara Therapeutics, Thomson Reuters, Wynn Resorts: 'Mad Money' Lightning Round

Jim Cramer is bullish on Cara Therapeutics, Thomson Reuters, Wynn Resorts, and Edison International.

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

It's just very hard to keep stocks down in this environment, says Jim Cramer. It's part of a synchronized global expansion.

MDGL Crosses Above Average Analyst Target

MDGL Crosses Above Average Analyst Target

In recent trading, shares of Madrigal Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $60.25, changing hands for $87.18/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results

Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results

- Top-line results from MGL-3196 Phase 2 clinical trials in NASH and HeFH expected in late 2017 and early 2018, respectively -

Madrigal Pharmaceuticals Presents Preclinical Results Supporting The Therapeutic Potential Of Its Lead ¿-Selective Thyroid Hormone Receptor Agonist, MGL-3196, At AASLD Liver Meeting

Madrigal Pharmaceuticals Presents Preclinical Results Supporting The Therapeutic Potential Of Its Lead ¿-Selective Thyroid Hormone Receptor Agonist, MGL-3196, At AASLD Liver Meeting

Results Demonstrate that MGL-3196 Provides Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term, High Fat Diet, Mouse NASH Model

Madrigal Pharmaceuticals is Now Oversold (MDGL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.